| 469.71 -0.97 (-0.21%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 579.6 | 1-year : | 603.8 |
| Resists | First : | 496.23 | Second : | 516.96 |
| Pivot price | 480.03  |
|||
| Supports | First : | 462.7 | Second : | 384.97 |
| MAs | MA(5) : | 471.48 |
MA(20) : | 480.24 |
| MA(100) : | 504.82 |
MA(250) : | 499.84 |
|
| MACD | MACD : | -6.5 |
Signal : | -5.6 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 15.7 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 583.39 | Low : | 372.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IDXX ] has closed above bottom band by 24.3%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 476.8 - 479.78 | 479.78 - 481.88 |
| Low: | 460.68 - 464.42 | 464.42 - 467.07 |
| Close: | 464.81 - 470.27 | 470.27 - 474.13 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Thu, 25 Jul 2024
BTIG Initiates Coverage of IDEXX Laboratories (WBAG:IDXX) with Buy Recommendation - Nasdaq
Thu, 25 Jul 2024
Analyst Ratings For IDEXX Laboratories - Benzinga
Thu, 25 Jul 2024
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Thu, 25 Jul 2024
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by National Bank of Canada FI - MarketBeat
Thu, 25 Jul 2024
IDEXX Laboratories (NASDAQ:IDXX) Coverage Initiated at BTIG Research - Defense World
Wed, 24 Jul 2024
IDEXX Laboratories Earnings Preview: What To Expect - Barchart
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 83 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 92.6 (%) |
| Shares Short | 2,690 (K) |
| Shares Short P.Month | 1,750 (K) |
| EPS | 10.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.93 |
| Profit Margin | 23.2 % |
| Operating Margin | 31 % |
| Return on Assets (ttm) | 22.6 % |
| Return on Equity (ttm) | 71.9 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 45.04 |
| EBITDA (p.s.) | 14.89 |
| Qtrly Earnings Growth | 10.1 % |
| Operating Cash Flow | 921 (M) |
| Levered Free Cash Flow | 733 (M) |
| PE Ratio | 45.6 |
| PEG Ratio | 3.5 |
| Price to Book value | 24.81 |
| Price to Sales | 10.42 |
| Price to Cash Flow | 42.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|